Gabapentin Tablet
Product Images NDC 71205-774

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71205-774). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Gabapentin 01)

Chemical structure diagram of the active ingredient Gabapentin. The image shows a cyclohexane ring bonded to an amine group (CH2NH2) and a carboxyl group (CH2CO2H), representing the molecular structure of Gabapentin.*

FDA Label Image

Figure 1 (Gabapentin 02)

A line graph showing mean pain scores over an 8-week period comparing placebo and Gabapentin at 3600 mg/day. The x-axis represents weeks from baseline to week 8. The y-axis shows mean pain scores from 0 to 10. Gabapentin data points form a decreasing curve, while placebo remains relatively stable. The graph divides the timeline into a 4-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Figure 2 (Gabapentin 03)

A line graph depicting mean pain scores over a 7-week period, comparing placebo with Gabapentin at daily doses of 1800 mg and 2400 mg. The x-axis represents weeks from baseline to week 7, and the y-axis shows mean pain scores ranging from 0 to 10. Two study phases are indicated: a 3-week dose titration period and a 4-week fixed dose period.*

FDA Label Image

Figure 3 (Gabapentin 04)

A bar chart titled 'Figure 3. Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies.' The chart compares placebo (PBO) to gabapentin (GBP) at doses 3600 mg in Study 1, and doses 1800 mg and 2400 mg in Study 2. The y-axis shows percentage responders from 0% to 100%. Gabapentin bars show higher responder percentages (29%, 32%, 34%) compared to placebo bars (12%, 14%). Statistical significance is indicated with asterisks for p-values less than 0.01 and 0.001.*

FDA Label Image

Figure 4 (Gabapentin 05)

A scatter plot graph depicting the percentage difference related to varying daily doses (mg) of Gabapentin, as studied in three separate studies labeled a, b, and c. The x-axis shows daily doses ranging from 600 to 1800 mg, and the y-axis shows the percentage difference from 2% to 22%. Each study is represented by different symbols: study a by black squares, study b by white squares with partial fill, and study c by empty squares.*

FDA Label Image

71205-774-90 (Gabapentin 07)

Label for Gabapentin 800 mg tablets by Proficient Rx LP, containing 90 tablets. The label states the product is prescription only and describes the tablets as white to off-white, modified capsule shape, biconvex, film-coated with debossed markings "SG" and "178" on opposite sides. It includes storage instructions and manufacturer details for ScieGen Pharmaceuticals, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.